

Market Announcement

2 August 2023

The Hydration Pharmaceuticals Company Limited (ASX: HPC) – Suspension from Quotation

Description

The securities of The Hydration Pharmaceuticals Company Limited ('HPC') will be suspended from quotation immediately under Listing Rule 17.2, at the request of HPC, pending the release of an announcement regarding a capital raising.

Issued by

Dale Wang

Adviser, Listings Compliance

2 August 2023

ASX Compliance Pty Ltd
Level 50, South Tower
Rialto, 525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

The Hydration Pharmaceuticals Company Limited (ASX: HPC) Request for Voluntary Suspension

We refer to the request for trading halt by The Hydration Pharmaceuticals Company Limited ACN 620 385 677 (the **Company** or **HPC**) on 31 July 2023 pending an announcement to be released to ASX by the Company regarding a capital raising.

Pursuant to Listing Rule 17.2, the Company requests a voluntary suspension of trading in its securities from the commencement of trading today, 2 August 2023.

In accordance with Listing Rule 17.2, the Company advises that:

1. The voluntary suspension is necessary to enable the Company to finalise arrangements in respect of the capital raising.
2. The Company expects the voluntary suspension to last for one trading day.
3. The Company will make an announcement to ASX regarding the capital raising pre-open on Thursday, 3 August 2023. Accordingly, the Company requests that the voluntary suspension continue until the commencement of normal trading on Thursday, 3 August 2023.
4. The Company is not aware of any reason why its securities should not be suspended, or of any other information available at this stage that is relevant to the voluntary suspension.

ENDS

This document was authorised for release by the Chair of HydraLyte North America.

For more information please contact:

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

About The Hydration Pharmaceuticals Company Limited

The Hydration Pharmaceuticals Company Limited (HPC) is a well-known brand developed in Australia in 2001 to produce a range of electrolyte-rich tablets, liquids and powders and aims to grow its footprint in new international markets, led by an experienced management team and high skilled Board of Directors. HydraLyte North America does not operate in Australia or New Zealand, where the brand is owned by Care Pharmaceuticals, but has exclusive rights to the HydraLyte brand in North and South America, Europe (excluding Turkey), China (excluding Taiwan) and Hong Kong. Current operations are focused on the United States and Canada, with headquarters in San Diego, California.